Drug Discovery World

MARCH 15, 2024

Valneva Scotland scooped two prizes at Scotland’s Life Sciences Awards 2024, including the award for Innovation – Pharma Services And Drug Discovery, in a ceremony on 14 March in Glasgow. Valneva also received the Outstanding Skills Development Award.

Life Science 59

Life Science Vaccination Vaccine Clinical Trials 59

XTalks

FEBRUARY 14, 2024

This episode features an interview with Yang Liu, PhD, founder, chairman, CEO and chief scientific officer; and Abid Ansari, MBA, Chief Financial Officer at OncoC4 , a clinical-stage biopharmaceutical company focused on developing novel treatments for cancer. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

Life Science 119

Life Science DNA Production Clinical Trials 119

Pharmaceutical Technology

AUGUST 15, 2022

It is no secret that Canada boasts a strong and competitive life sciences sector. Within Canada, one province has often stood out as the place to be for cutting-edge life sciences innovation. Canada’s next life sciences leader. Again, this is nothing new. Now, there is no slowing down.

Life Science 130

Life Science Research Manufacturing Insulin 130

Drug Discovery World

SEPTEMBER 4, 2023

AviadoBio, a gene therapy company developing medicines for neurodegenerative disorders, will establish laboratory and office presence at the Innovation Centre. Kadans and Canary Wharf Group are also progressing their joint venture to develop an GIA commercial health and life sciences building, the largest in Europe, on the 3.3-hectare

Life Science 59

Life Science Gene Therapy Genome Genomics 59

Drug Discovery World

MARCH 16, 2023

There was some good news for the UK life sciences sector in the government’s Spring Budget, but did it go far enough? Regulation for medicines There were significant changes announced regarding the UK’s medicines regulator, the Medicines and Healthcare Regulatory Agency (MHRA).

Life Science 97

Life Science Regulation Medicine Research 97

XTalks

MAY 15, 2024

Ovid Therapeutics is a biopharmaceutical company focused on the development of medicines for epilepsies and seizure-related neurological disorders. Dr. Levin has practiced medicine at university hospitals in England, South Africa and Switzerland. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

Life Science 69

Life Science Medicine Clinical Research Development 69

Pharmaceutical Technology

APRIL 12, 2023

Cognizant and Boehringer Ingelheim are collaborating on an integrated cloud platform to enhance the speed and quality of medicinal therapy development. Cognizant will leverage the Veeva Development Cloud platform to help Boehringer Ingelheim to merge medicinal development processes and data into a connected technology ecosystem.

Medicine 130

Medicine Life Science Development Branding 130

XTalks

MAY 8, 2024

In this episode, Ayesha spoke with William Schaffner, MD, Professor of Preventive Medicine Health Policy and Professor in the Division of Infectious Diseases at Vanderbilt University; and Kelly Moore, MD, MPH, President and CEO at Immunize.org and Associate Professor of Health Policy at Vanderbilt University.

Life Science 95

Life Science Vaccination Vaccine Medicine 95

Pharmaceutical Technology

FEBRUARY 15, 2023

JSR Life Sciences’ business unit Similis Bio is planning to collaborate with Novel351k for the development of three biosimilar programmes targeting cancer and autoimmune diseases. Under the terms of the initial deal, Similis Bio will handle the development of cell lines, analytics, process development, and cGMP production.

Development 147

Development Life Science Manufacturing Clinical Trials 147

Pharmaceutical Technology

APRIL 10, 2023

Aviceda Therapeutics (Aviceda) has entered into a strategic partnership with the Patrick G Johnston Centre for Cancer Research at Queen’s University Belfast (QUB) for the development of next-generation glyco-immune therapeutics. Aviceda Glycotech has been created as an oncology-focused spin-off company from Aviceda Therapeutics and Queen’s.

Development 259

Development Life Science Clinical Trials Clinical Trials 259

XTalks

SEPTEMBER 6, 2023

David Young, founder and President R&D at Processa Pharmaceuticals, a clinical-stage pharmaceutical company developing personalized approaches to cancer treatments with a focus on next generation chemotherapy drugs with improved safety and efficacy. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

Life Science 116

Life Science Drugs Development Research 116

BioPharma Reporter

DECEMBER 16, 2022

GSK and genetic medicines company, Wave Life Sciences, have announced a strategic collaboration to advance oligonucleotide therapeutics across multiple disease areas.

Life Science 52

Life Science Development Genetics Medicine 52

Drug Discovery World

MAY 16, 2024

million development in Manchester intended to enhance the city’s Oxford Road Corridor knowledge quarter as a hub for life sciences and technology innovation. Greenheys at Manchester Science Park is scheduled for completion in Summer 2026 and will span 131,000 sq ft across six floors. Work has started on a £60 ($75.1)

Biobanking 59

Biobanking Development Life Science Genome 59

XTalks

AUGUST 23, 2023

This episode features an interview with Dr. William Williams, CEO of BriaCell Therapeutics, a biotech company based in Philadelphia that is dedicated to developing novel immunotherapies to fight cancer and improve patient lives. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

Life Science 98

Life Science Clinical Trials Clinical Trials FDA Approval 98

Drug Discovery World

JULY 4, 2023

Vesalius Biocapital, a life sciences venture capital investor, has closed its fourth fund, Vesalius Biocapital IV, securing over €95 million of commitments. The company plans to invest in first and best-in-class European life science companies in drug development and digital health.

Life Science 52

Life Science Sales Development Medicine 52

XTalks

DECEMBER 20, 2023

In 2023, there were significant advancements and notable trends in the life sciences. These advancements and trends addressed important industry challenges and offered opportunities to foster innovations and solutions in areas including drug development, healthcare and medical devices. billion in 2022.

Life Science 59

Life Science Clinical Trials Clinical Trials FDA Approval 59

XTalks

JANUARY 10, 2024

Dr. Kaplin transitioned into industry by joining MIRA Pharmaceuticals to help lead drug development in the space. He also served as Co-Founder of numerous healthcare related startups, including, from 2018 to present, REWARD Pathways, a company devoted to addiction treatment focused on a combined eHealth and medicine approach.

Life Science 52

Life Science Development Drugs Medicine 52

pharmaphorum

MAY 9, 2024

A UK report has said that inflation and geopolitical instability have led to a “dramatic drop” in investment in smaller companies developing new medicines, with a knock-on effect on the entire life sciences industry.

Life Science 117

Life Science Drugs Medicine Development 117

Pharmaceutical Technology

MAY 4, 2023

Forge Biologics and global life sciences company Labcorp have announced a strategic adeno-associated virus (AAV) gene therapy development and manufacturing collaboration. This will improve accessibility to services for AAV-mediated gene therapy programmes.

Gene Therapy 256

Gene Therapy Gene Development Manufacturing 256

XTalks

MARCH 8, 2022

On International Women’s Day, Xtalks is celebrating women’s leadership in the life sciences by highlighting some of the female leaders at the forefront of scientific discovery, as well as the continuing challenges of attaining more equitable representation. Challenges in Women’s Leadership.

Life Science 105

Life Science Gene Therapy DNA Vaccination 105

Drug Discovery World

JULY 8, 2022

? Work has started on the first wholly speculative development of new multi-let laboratory and office space at Cambridge Biomedical Campus in the UK, which is specifically targeting a range of growing biotech and life science businesses. .

Life Science 52

Life Science Development Medicine Scientist 52

Pharmaceutical Technology

OCTOBER 28, 2022

Drug discovery and development is an incredibly expensive and time-consuming process, taking between 12 and 18 years, and costing on average between $2 billion and $3 billion. Robots can improve drug discovery and development.

Development 311

Development Drugs Pharma Companies Life Science 311

pharmaphorum

MARCH 8, 2022

How did you get into life sciences? After a few years, I decided I wanted to move into the commercial side of the business, so I completed an MBA and went on to hold various positions in Corporate Business Development, Life Science and Healthcare. What has your career path been?

Life Science 98

Life Science Engineer Scientist Doctors 98

pharmaphorum

OCTOBER 12, 2022

Now, he leads Whitelab Genomics as its artificial intelligence (AI) platform powers the development of genomic therapies – an emerging field in which genetic sequences are injected into cells to target and repair damaged genes. The evolving field of genomic medicine.

Genome 105

Genome Genomics Medicine Development 105

Pharmaceutical Technology

MAY 24, 2023

Forge Biologics has joined the public-private collaboration, the Bespoke Gene Therapy Consortium (BGTC), to expedite the development and manufacture of new AAV [adeno-associated virus] gene therapies to treat patients with rare diseases. Shilling was appointed to represent the company on the steering committee of the BGTC.

Gene Therapy 242

Gene Therapy Gene Development Manufacturing 242

Pharmaceutical Technology

JULY 1, 2022

Blueprint Medicines has entered strategic financing partnerships for up to $1.25bn with life sciences-focused investors Sixth Street and Royalty Pharma. The funding will offer capital to extend Blueprint’s varied pipeline toward marketing as well as to continue seeking strategic and synergistic business development prospects.

Medicine 147

Medicine Business Development Sales Life Science 147

XTalks

JUNE 14, 2023

This episode features an interview with Dr. Courtney Silverthorn who is an Associate Vice President at the Foundation for the National Institutes of Health (FNIH) and the Director of the Accelerating Medicines Partnership (AMP) program including the Bespoke Gene Therapy Consortium.

Gene Therapy 98

Gene Therapy Life Science Gene Clinical Trials 98

pharmaphorum

MARCH 12, 2021

If the power of the life sciences industry to innovate and collaborate were ever in doubt, the speed at which vaccines for COVID-19 were discovered, developed, trialled, approved and manufactured have confirmed just how dynamic the industry can be. And those volumes will only increase. Cloud for data-fuelled business growth.

Life Science 111

Life Science Regulation Genome Genomics 111

Pharmaceutical Technology

OCTOBER 12, 2022

Neumora Therapeutics has raised $112m in a Series B financing round to advance its new precision medicine candidates pipeline for neuropsychiatric disorders and neurodegenerative diseases. The company also intends to use the funding to develop its precision neuroscience platform. Neumora has raised nearly $650m in capital to date.

Development 147

Development Life Science Clinical Trials Clinical Trials 147

pharmaphorum

JULY 22, 2022

A just-published report on the UK’s life sciences sector “ought to ring alarm bells across government,” according to the Association of the British Pharmaceutical Industry (SBPI). The Life Sciences Competitiveness Indicators report shows that spending on life sciences R&D was £2.7

Life Science 52

Life Science Clinical Trials Clinical Trials Medicine 52

XTalks

DECEMBER 29, 2022

The life sciences and healthcare are among the biggest industries globally, and their significance was particularly highlighted during the past couple of years by the COVID-19 pandemic. Given the hyperfocus on the life sciences thanks to COVID, consumers appear to be more autonomous and vocal about their medical demands and choices.

Life Science 52

Life Science Gene Therapy Gene Manufacturing 52

pharmaphorum

MARCH 30, 2022

The organisation behind the iconic Canary Wharf development has said it plans to build one of the largest commercial laboratory facilities in Europe as part of a drive to make the east London site a hub for the life sciences sector. building dedicated to a combination of wet lab and office space.

Life Science 59

Life Science Development Medicine Research 59

pharmaphorum

JULY 19, 2021

A new report published by Medicines Discovery Catapult and CPI details the huge medical and market potential for complex medicines in the UK. A complex medicine applies novel technologies that deliver or target drugs, by modification of a pharmaceutical ingredient, formulation or using a new delivery route.

Life Science 52

Life Science Medicine RNA Vaccination 52

XTalks

DECEMBER 13, 2023

This episode features an interview with vaccine scientists and executives from Vaccines Global Clinical Development at Merck, Dr. Heather Platt, MD, Distinguished Scientist and Pneumococcal Vaccine Lead; and Dr. Ulrike Buchwald, MD, Scientific Associate Vice President, Global Clinical Research and Pneumococcal Vaccine Section Head.

Life Science 52

Life Science Vaccination Vaccine Scientist 52

XTalks

NOVEMBER 15, 2023

This episode features an interview with Dr. Lahar Mehta, Head of Global Clinical Development at Amylyx Pharmaceuticals, who spoke to Xtalks about Amylyx’s clinical trial design of ORION, a Phase III Global Study of AMX0035 (Relyvrio) in Progressive Supranuclear Palsy (PSP). There are currently no approved medicines to treat PSP.

Life Science 52

Life Science Trials Clinical Trials Clinical Trials 52

XTalks

OCTOBER 12, 2022

In this episode, Ayesha and the editorial team spoke with Caroline Hamilton, Clinical Director of Neuromod Devices , a medical technology company that specializes in the design and development of neuromodulation technologies. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

Life Science 98

Life Science Development Clinical Trials Clinical Trials 98

XTalks

MARCH 1, 2023

In this week’s Xtalks Life Science podcast episode, Sarah spoke with Doug Biehn, Chief Commercial Officer at Cala Health , a bioelectronic medicine company that develops wearable neuromodulation therapies. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

Life Science 52

Life Science Medicine Production Development 52